New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
05:23 EDTSHPGShire executes agreements to divest Dermagraft
Shire announced that it has entered into a definitive agreement pursuant to which it has sold its Dermagraft assets to Organogenesis. Dermagraft is a living skin substitute indicated for use in the treatment of full-thickness diabetic foot ulcers and is approved for use in the US and Canada. Going forward Organogenesis will assume all financial and management responsibility for Dermagraft. The Dermagraft assets that have been sold to Organogenesis comprise the key operating assets relating to the development, manufacture and sale of the Dermagraft product. These assets include intellectual property relating to Dermagraft including patents, trademarks and know-how; regulatory filings and registrations relating to Dermagraft; certain manufacturing plant, equipment and materials; Dermagraft product inventory and accounts receivable. These assets had a value of $683M in Shire's September 30, 2013 balance sheet. Shire is generally retaining legacy liabilities relating to the Dermagraft business, including the previously announced Department of Justice investigation relating to the sales and marketing practices of Advanced Biohealing. Shire will receive no upfront payment from Organogenesis but is entitled to receive up to $300M cash in total milestone payments should Organogenesis meet certain annual net sales targets between now and 2018. Shire will record a loss on disposal and associated impairment charges of approximately $650M in Q4, which will be excluded from Non GAAP earnings.
News For SHPG From The Last 14 Days
Check below for free stories on SHPG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent SHPG news | >>
July 14, 2014
16:30 EDTSHPGOn The Fly: Closing Wrap
Subscribe for More Information
16:18 EDTSHPGShire shareholders should support latest AbbVie offer, Telegraph says
Subscribe for More Information
10:00 EDTSHPGOptions with decreasing implied volatility: SHPG INFY CWH FDO IDIX FAST
09:55 EDTSHPGHigh option volume stocks: PTEN MFRM GTIV SHPG IMMR
09:16 EDTSHPGOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
06:03 EDTSHPGStocks with implied volatility below IV index mean; BBBY SHPG
Subscribe for More Information
05:27 EDTSHPGShire receives revised proposal from AbbVie of GPB 53.20 per share
Subscribe for More Information
July 13, 2014
17:10 EDTSHPGShire said to seek bid of near 53 pounds per share from AbbVie, Reuters says
Subscribe for More Information
July 11, 2014
16:46 EDTSHPGStocks end week lower on European, Fed concerns
Subscribe for More Information
14:13 EDTSHPGShire, AbbVie didn't commit to further talks, Dow reports
Subscribe for More Information
13:58 EDTSHPGShire confirms meeting with AbbVie representatives
Subscribe for More Information
11:54 EDTSHPGAbbVie, Shire in active takeover talks, Bloomberg reports
AbbVie (ABBV) and Shire (SHPG) are in active talks about a potential merger after AbbVie raised its takeover offer for a fourth time, Bloomberg reports, citing people with knowledge of the matter. The talks are in the early stage and may not lead to an agreement, sources told Bloomberg. Shares of Shire are up 5%, or $12.04, to $250.65 following the report.
11:34 EDTSHPGShire jumps 5% after Bloomberg report on talks with AbbVie
11:33 EDTSHPGShire, AbbVie held talks after latest raised takeover offer, Bloomberg says
Subscribe for More Information
July 10, 2014
09:40 EDTSHPGAbbVie, Shire not holding talks at this point as deadline approaches, CNBC says
AbbVie (ABBV) and Shire (SHPG) are not holding talks at this point, according to CNBC's David Faber, citing sources. Shire confirmed two days ago that it has received AbbVie's latest, raised takeover offer and that its board will meet to consider the proposal.
July 9, 2014
18:31 EDTSHPGShareholders urge Allergan to make large acquisition, FT reports
Subscribe for More Information
18:21 EDTSHPGAllergan CEO seeks sizeable acquisitions, WSJ reports
Subscribe for More Information
08:19 EDTSHPGAbbVie offer may not bring Shire to negotiating table, says BMO Capital
Subscribe for More Information
07:38 EDTSHPGShire still has leverage, can get one more raise from AbbVie, Reuters contends
The selloff in shares of Shire (SHPG) and AbbVie (ABBV) yesterday following the latter's increased takeover offer suggests the market now expects a strong rebuttal from Shire, but "one plausible response" is a gently worded rejection that signals that another raised bid would be enough to secure a deal without a hostile play, contended Reuters Breakingviews columnists Neil Unmack and Robert Cyran. Shire’s board still has some leverage and can "probably extract one more increase in return for their recommendation," the authors believe. Reference Link
06:40 EDTSHPGAbbVie required to retract comments in Shire takeover battle, Reuters says
AbbVie (ABBV) has been required to take back comments made by its CEO Richard Gonzalez regarding shareholder support for its offer for Shire (SHPG), according to Reuters, citing a statement from the U.S. drugmaker. British takeover rules say that a rival is not allowed to claim support for its bid unless it has this in writing from shareholders. Reference Link
1 | 2 | 3 | all recent SHPG news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use